AXIM Biotechnologies, Inc. announced that the Company has received an additional order for its electronic readers designed to analyze both of the Company?s proprietary diagnostics assays from its commercialization partner Verséa Ophthalmics.  The re-order of readers marks a pivotal milestone in AXIM?s expanding clinical presence and re-occurring revenue opportunity.AXIM?s commercialization partner Verséa Ophthalmics has been ramping up sales of the Company?s proprietary, FDA-cleared ocular diagnostic assays in recent months. Both its ocular T-POC TOTAL IgE Immunoassay and T-POC LACTOFERRIN Immunoassay Kits use an electronic reader to analyze the results of tear samples at the point-of-care. Verséa Ophthalmics?

reorder of these readers indicates an impending clinical expansion of AXIM?s diagnostic program. Most clinics require at least two readers to efficiently perform both tests. Once a clinic receives a reader it must undergo a validation prior to its clinical use.

The recent reorder reflects the successful clinical validation and implementation of the reader platform. AXIM expects clinics to perform approximately 150 tests per month. The reorder made by Verséa indicates that they have sold and/or disbursed the majority of their original inventory of readers to clinics and foresees additional interest in the platform from new clinics.  Both of AXIM?s ocular diagnostic assays were designed to provide clinicians with a tool to both diagnosis and properly treat Dry Eye Disease (DED) at the point-of-care, a previously unavailable solution.

The tests quantitatively measure two different indicators in patient tear samples which have been shown to assist clinicians in proper diagnosis of DED, and render result in nine minutes. DED is historically under or mis-diagnosed with estimates that between 5%-15% of the entire US population show symptoms consistent with DED. AXIM?s platform seeks to close this diagnosis gap through its affordable, accurate, and point-of-care platform.